Company registration number SC214573 (Scotland)
ARGYLL PHARMACIES LIMITED
UNAUDITED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2025
PAGES FOR FILING WITH REGISTRAR
ARGYLL PHARMACIES LIMITED
CONTENTS
Page
Balance sheet
1 - 2
Notes to the financial statements
3 - 7
ARGYLL PHARMACIES LIMITED
BALANCE SHEET
AS AT
31 MARCH 2025
31 March 2025
- 1 -
2025
2024
Notes
£
£
£
£
Fixed assets
Intangible assets
3
372,613
421,253
Tangible assets
4
114,797
15,958
487,410
437,211
Current assets
Stocks
78,082
89,637
Debtors
5
678,317
566,786
Cash at bank and in hand
201,713
142,817
958,112
799,240
Creditors: amounts falling due within one year
6
(406,111)
(280,734)
Net current assets
552,001
518,506
Total assets less current liabilities
1,039,411
955,717
Provisions for liabilities
(13,737)
(3,989)
Net assets
1,025,674
951,728
Capital and reserves
Called up share capital
7
2
2
Profit and loss reserves
1,025,672
951,726
Total equity
1,025,674
951,728
ARGYLL PHARMACIES LIMITED
BALANCE SHEET (CONTINUED)
AS AT
31 MARCH 2025
31 March 2025
- 2 -
For the financial year ended 31 March 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.
The members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476.
The director acknowledges her responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.
These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.
The director of the company has elected not to include a copy of the profit and loss account within the financial statements.true
The financial statements were approved and signed by the director and authorised for issue on 18 December 2025
Ms S Paterson
Director
Company registration number SC214573 (Scotland)
ARGYLL PHARMACIES LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2025
- 3 -
1
Accounting policies
Company information
Argyll Pharmacies Limited is a private company limited by shares incorporated in Scotland. The registered office is 12/14 Argyll Street, Lochgilphead, Argyll, United Kingdom, PA31 8LZ.
1.1
Accounting convention
These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime. The disclosure requirements of section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.
The financial statements are prepared in sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £.
The financial statements have been prepared under the historical cost convention.
1.2
Turnover
Turnover is recognised at the fair value of the consideration received or receivable for goods and services provided in the normal course of business, and is shown net of VAT and other sales related taxes. The fair value of consideration takes into account trade discounts, settlement discounts and volume rebates.
1.3
Intangible fixed assets - goodwill
Goodwill represents the excess of the cost of acquisition of unincorporated businesses over the fair value of net assets acquired. It is initially recognised as an asset at cost and is subsequently measured at cost less accumulated amortisation and accumulated impairment losses. Goodwill is considered to have a finite useful life and is amortised on a systematic basis over its expected life, which is 10 years.
1.4
Tangible fixed assets
Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.
Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:
Plant and equipment
15% Reducing balance
Fixtures and fittings
33% Straight line
Computers
25% Straight line
Motor vehicles
25% Reducing balance
The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is credited or charged to profit or loss.
1.5
Impairment of fixed assets
At each reporting period end date, the company reviews the carrying amounts of its tangible and intangible assets to determine whether there is any indication that those assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss (if any).
1.6
Stocks
Stocks are stated at the lower of cost and estimated selling price less costs to complete and sell, after making due allowance for obsolete and slow moving items.
ARGYLL PHARMACIES LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2025
1
Accounting policies
(Continued)
- 4 -
At each reporting date, an assessment is made for impairment. Any excess of the carrying amount of stocks over its estimated selling price less costs to complete and sell is recognised as an impairment loss in profit or loss. Reversals of impairment losses are also recognised in profit or loss.
1.7
Equity instruments
Equity instruments issued by the company are recorded at the proceeds received, net of transaction costs. Dividends payable on equity instruments are recognised as liabilities once they are no longer at the discretion of the company.
1.8
Taxation
The tax expense represents the sum of the tax currently payable and deferred tax.
Current tax
The tax currently payable is based on taxable profit for the year. Taxable profit differs from net profit as reported in the profit and loss account because it excludes items of income or expense that are taxable or deductible in other years and it further excludes items that are never taxable or deductible. The company’s liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the reporting end date.
Deferred tax
Deferred tax liabilities are generally recognised for all timing differences and deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Such assets and liabilities are not recognised if the timing difference arises from goodwill or from the initial recognition of other assets and liabilities in a transaction that affects neither the tax profit nor the accounting profit.
The carrying amount of deferred tax assets is reviewed at each reporting end date and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered. Deferred tax is calculated at the tax rates that are expected to apply in the period when the liability is settled or the asset is realised. Deferred tax is charged or credited in the profit and loss account, except when it relates to items charged or credited directly to equity, in which case the deferred tax is also dealt with in equity. Deferred tax assets and liabilities are offset when the company has a legally enforceable right to offset current tax assets and liabilities and the deferred tax assets and liabilities relate to taxes levied by the same tax authority.
1.9
Employee benefits
The costs of short-term employee benefits are recognised as a liability and an expense, unless those costs are required to be recognised as part of the cost of stock or fixed assets.
The cost of any unused holiday entitlement is recognised in the period in which the employee’s services are received.
1.10
Retirement benefits
Payments to defined contribution retirement benefit schemes are charged as an expense as they fall due.
1.11
Leases
As lessee
Rentals payable under operating leases, including any lease incentives received, are charged to profit or loss on a straight line basis over the term of the relevant lease except where another more systematic basis is more representative of the time pattern in which economic benefits from the leases asset are consumed.
ARGYLL PHARMACIES LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2025
1
Accounting policies
(Continued)
- 5 -
1.12
Foreign exchange
Transactions in currencies other than pounds sterling are recorded at the rates of exchange prevailing at the dates of the transactions. At each reporting end date, monetary assets and liabilities that are denominated in foreign currencies are retranslated at the rates prevailing on the reporting end date. Gains and losses arising on translation in the period are included in profit or loss.
2
Employees
The average monthly number of persons (including directors) employed by the company during the year was:
2025
2024
Number
Number
Total
14
14
3
Intangible fixed assets
Goodwill
£
Cost
At 1 April 2024 and 31 March 2025
496,395
Amortisation and impairment
At 1 April 2024
75,142
Amortisation charged for the year
48,640
At 31 March 2025
123,782
Carrying amount
At 31 March 2025
372,613
At 31 March 2024
421,253
ARGYLL PHARMACIES LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2025
- 6 -
4
Tangible fixed assets
Plant and equipment
Fixtures and fittings
Computers
Motor vehicles
Total
£
£
£
£
£
Cost
At 1 April 2024
11,847
2
21,276
31,566
64,691
Additions
28,937
69,416
14,700
113,053
Disposals
(18,500)
(18,500)
At 31 March 2025
40,784
69,418
21,276
27,766
159,244
Depreciation and impairment
At 1 April 2024
10,767
1
20,965
17,000
48,733
Depreciation charged in the year
162
1
220
1,943
2,326
Eliminated in respect of disposals
(6,612)
(6,612)
At 31 March 2025
10,929
2
21,185
12,331
44,447
Carrying amount
At 31 March 2025
29,855
69,416
91
15,435
114,797
At 31 March 2024
1,080
1
311
14,566
15,958
5
Debtors
2025
2024
Amounts falling due within one year:
£
£
Trade debtors
161,764
178,556
Other debtors
516,553
388,230
678,317
566,786
6
Creditors: amounts falling due within one year
2025
2024
£
£
Trade creditors
274,801
187,311
Taxation and social security
43,985
49,040
Other creditors
87,325
44,383
406,111
280,734
7
Called up share capital
2025
2024
2025
2024
Ordinary share capital
Number
Number
£
£
Issued and fully paid
Ordinary Shares of £1 each
2
2
2
2
ARGYLL PHARMACIES LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2025
- 7 -
8
Secured Debts
A bond and floating charge over the assets of the company has been granted, as well as a guarantee for £769,000, to secure the loan received by Ensco 436 Limited, the parent company in favour of The Royal Bank of Scotland plc. The loan provided to Ensco 436 Limited assisted with the acquisition of the business and Goodwill of Argyll Pharmacies Limited.
9
Related party transactions
Transactions with related parties
During the year the company entered into the following transactions with related parties:
2025
2024
£
£
Amount due from related parties
410,372
328,932
The above loan is unsecured, interest free and has no fixed terms of repayment.
The following amounts were outstanding at the reporting end date:
2025
2024
Amounts due to related parties
£
£
Key management personnel
32,641
38,502
The following amounts were outstanding at the reporting end date: